Skip to main content
Erschienen in: Clinical Rheumatology 5/2016

14.03.2016 | Brief Report

The IgM isotype of anti-annexin A5 antibodies and multiple positivity of conventional antiphospholipid antibodies: increasing the number of clinical manifestations of primary antiphospholipid syndrome

verfasst von: Mirjana Bećarević, Ljudmila Stojanović, Svetlana Ignjatović, Violeta Dopsaj

Erschienen in: Clinical Rheumatology | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Abstract

We evaluated the importance of anti-annexin A5 antibodies (aanxA5 Abs) for clinical (thrombosis and/or recurrent pregnancy loss) and serologic (presence of antiphospholipid antibodies: lupus anticoagulant (LA), anticardiolipin (aCL), and anti-β2 glycoprotein I (aβ2GPI) antibodies) features of patients with primary antiphospholipid syndrome (PAPS). Our study included 70 patients with PAPS according to the international consensus criteria for APS. The mean age of the analyzed patients was 45.97 ± 12.72. The disease duration above 5 years was present in 31/70 of patients. Concentrations of analyzed antibodies were measured by ELISA. Cutoff values were set in accordance to the manufacturers’ recommendations. History of recurrent pregnancy loss was associated with double positivity for aanxA5 IgM and LA (χ 2 = 4.000, P = 0.046) and triple positivity for aanxA5 IgM + LA + aβ2GPI IgM (χ 2 = 4.168, P = 0.041). Venous thromboses were associated with triple positivity for aanxA5 IgM + aCLIgG + aβ2GPI IgM (χ 2 = 3.965, P = 0.046). The IgG isotype of aanxA5 Abs was in positive correlation with aCL Abs of the IgG (r = 0.310, P = 0.009) and IgM (r = 0.254, P = 0.034) isotype. The presence of the clinical manifestations of PAPS is increasing with the number of positive conventional aPL and the IgM aanxA5 Abs tests. This new combination of Abs is beneficial even when the number of patients with positivity for aanxA5 Abs is low. This is important in further detection of patients prone to recurrence of thrombotic episodes.
Literatur
2.
Zurück zum Zitat Bertolaccini ML, Amengual O, Andreoli L, Atsumi T, Chighizola CB, Forastiero R et al (2014) 14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmun Rev 13:917–930CrossRefPubMed Bertolaccini ML, Amengual O, Andreoli L, Atsumi T, Chighizola CB, Forastiero R et al (2014) 14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmun Rev 13:917–930CrossRefPubMed
3.
Zurück zum Zitat Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost 4:295–306CrossRefPubMed Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost 4:295–306CrossRefPubMed
4.
Zurück zum Zitat Pengo V, Banzato A, Denas G et al (2013) Correct laboratory approach to APS diagnosis and monitoring. Autoimmun Rev 12:832–834CrossRefPubMed Pengo V, Banzato A, Denas G et al (2013) Correct laboratory approach to APS diagnosis and monitoring. Autoimmun Rev 12:832–834CrossRefPubMed
5.
Zurück zum Zitat Forastiero R (2014) Multiple antiphospholipid antibodies positivity and antiphospholipid syndrome criteria re-evaluation. Lupus 23(12):1252–4CrossRefPubMed Forastiero R (2014) Multiple antiphospholipid antibodies positivity and antiphospholipid syndrome criteria re-evaluation. Lupus 23(12):1252–4CrossRefPubMed
6.
Zurück zum Zitat Hernández-Molina G, Espericueta-Arriola G, Cabral AR (2013) The role of lupus anticoagulant and triple marker positivity as risk factors for rethrombosis in patients with primary antiphospholipid syndrome. Clin Exp Rheumatol 31(3):382–8PubMed Hernández-Molina G, Espericueta-Arriola G, Cabral AR (2013) The role of lupus anticoagulant and triple marker positivity as risk factors for rethrombosis in patients with primary antiphospholipid syndrome. Clin Exp Rheumatol 31(3):382–8PubMed
7.
Zurück zum Zitat Nayfe R, Uthman I, Aoun J, Aldin ES, Merashil M, Khamashta MA (2013) Seronegative antiphospholipid syndrome. Rheumatology 52:1358–1367CrossRefPubMed Nayfe R, Uthman I, Aoun J, Aldin ES, Merashil M, Khamashta MA (2013) Seronegative antiphospholipid syndrome. Rheumatology 52:1358–1367CrossRefPubMed
8.
Zurück zum Zitat de Laat B, Wu XX, van Lummel M, Derksen RHWM, de Groot PG, Rand JH (2007) Correlation between antiphospholipid antibodies that recognize domain I of beta2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5. Blood 109:1490–4CrossRefPubMed de Laat B, Wu XX, van Lummel M, Derksen RHWM, de Groot PG, Rand JH (2007) Correlation between antiphospholipid antibodies that recognize domain I of beta2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5. Blood 109:1490–4CrossRefPubMed
9.
Zurück zum Zitat Brandt JT, Triplett DA, Alving B, Scharrer J (1995) Criteria for the diagnosis of lupus anticoagulants: an update on behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipd Antibody of the Scientific and Standardisation Committee of the International Society of Thrombosis and Haemostasis. Thromb Haemost 74(4):1185–90PubMed Brandt JT, Triplett DA, Alving B, Scharrer J (1995) Criteria for the diagnosis of lupus anticoagulants: an update on behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipd Antibody of the Scientific and Standardisation Committee of the International Society of Thrombosis and Haemostasis. Thromb Haemost 74(4):1185–90PubMed
10.
Zurück zum Zitat Galli M, Luciani D, Bertolini G, Barbui T (2003) Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 101(5):1827–32CrossRefPubMed Galli M, Luciani D, Bertolini G, Barbui T (2003) Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 101(5):1827–32CrossRefPubMed
11.
Zurück zum Zitat Forastiero R, Martinuzzo M, Pombo G, Puente D, Rossi A, Celebrin L et al (2005) A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and a risk of thrombosis. J Thromb Haemost 3(6):1231–8CrossRefPubMed Forastiero R, Martinuzzo M, Pombo G, Puente D, Rossi A, Celebrin L et al (2005) A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and a risk of thrombosis. J Thromb Haemost 3(6):1231–8CrossRefPubMed
12.
13.
Zurück zum Zitat Nasef A, Ibrahim M, Riad N, Mousa S (2014) Plasma annexin A5, anti-annexin A5 antibodies and annexin A5 polymorphism in Egyptian female patients with systemic lupus erythematosus and antiphospholipid syndrome. Clin Lab 60(1):133–7PubMed Nasef A, Ibrahim M, Riad N, Mousa S (2014) Plasma annexin A5, anti-annexin A5 antibodies and annexin A5 polymorphism in Egyptian female patients with systemic lupus erythematosus and antiphospholipid syndrome. Clin Lab 60(1):133–7PubMed
14.
Zurück zum Zitat Gris JC, Bouvier S (2013) Antiphospholipid syndrome: looking for a refocusing. Thromb Res 131(1):S28–S31CrossRefPubMed Gris JC, Bouvier S (2013) Antiphospholipid syndrome: looking for a refocusing. Thromb Res 131(1):S28–S31CrossRefPubMed
15.
Zurück zum Zitat De Laat B, Derksen RHWM, Mackie IJ et al (2006) Annexin A5 polimorphism (−1C > T) and the presence of anti-annexin A5 antibodies in the antiphospholipid syndrome. Ann Rheum Dis 65(11):1468–72CrossRefPubMedPubMedCentral De Laat B, Derksen RHWM, Mackie IJ et al (2006) Annexin A5 polimorphism (−1C > T) and the presence of anti-annexin A5 antibodies in the antiphospholipid syndrome. Ann Rheum Dis 65(11):1468–72CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Amaral M, Favas C, Delgado Alves J (2010) Persistency of low levels of anticardiolipin and anti-beta2 glycoprotein 1 in thrombosis. Eur J Intern Med 21:101–103CrossRefPubMed Amaral M, Favas C, Delgado Alves J (2010) Persistency of low levels of anticardiolipin and anti-beta2 glycoprotein 1 in thrombosis. Eur J Intern Med 21:101–103CrossRefPubMed
17.
Zurück zum Zitat Mekinian A, Loire-Berson P, Nicaise-Roland P, Lachassinne E, Stirnrmann J, Boffa MC et al (2012) Outcomes and treatment of obstetrical antiphospholipid syndrome in women with low antiphospholipid antibody levels. J Reprod Immunol 94:222–226CrossRefPubMed Mekinian A, Loire-Berson P, Nicaise-Roland P, Lachassinne E, Stirnrmann J, Boffa MC et al (2012) Outcomes and treatment of obstetrical antiphospholipid syndrome in women with low antiphospholipid antibody levels. J Reprod Immunol 94:222–226CrossRefPubMed
18.
Zurück zum Zitat Boffa MC, Boinot C, De Carolis S, Rovere-Querini P, Aurousseau MH, Allegri F et al (2009) Laboratory criteria of the obstetrical antiphospholipid syndrome. Data from a multicentric prospective European women cohort. Thromb Haemost 102:25–28PubMed Boffa MC, Boinot C, De Carolis S, Rovere-Querini P, Aurousseau MH, Allegri F et al (2009) Laboratory criteria of the obstetrical antiphospholipid syndrome. Data from a multicentric prospective European women cohort. Thromb Haemost 102:25–28PubMed
19.
Zurück zum Zitat Pengo V (2011) Antiphospholipid syndrome: interpretation of laboratory data. J Thromb Haemost 9(2):402–3CrossRefPubMed Pengo V (2011) Antiphospholipid syndrome: interpretation of laboratory data. J Thromb Haemost 9(2):402–3CrossRefPubMed
20.
Zurück zum Zitat Kist WJ, Janssen NG, Kalk JJ, Hague WM, Dekker GA, de Vries JL (2008) Thrombophilias and adverse pregnancy outcome—a confounded problem. Thromb Haemost 99:77–85PubMed Kist WJ, Janssen NG, Kalk JJ, Hague WM, Dekker GA, de Vries JL (2008) Thrombophilias and adverse pregnancy outcome—a confounded problem. Thromb Haemost 99:77–85PubMed
Metadaten
Titel
The IgM isotype of anti-annexin A5 antibodies and multiple positivity of conventional antiphospholipid antibodies: increasing the number of clinical manifestations of primary antiphospholipid syndrome
verfasst von
Mirjana Bećarević
Ljudmila Stojanović
Svetlana Ignjatović
Violeta Dopsaj
Publikationsdatum
14.03.2016
Verlag
Springer London
Erschienen in
Clinical Rheumatology / Ausgabe 5/2016
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-016-3230-0

Weitere Artikel der Ausgabe 5/2016

Clinical Rheumatology 5/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.